News

Foley Hoag Partner Bryant Godfrey Named to FDLI Board of Directors

January 18, 2024

Foley Hoag LLP Partner Bryant Godfrey has been named an At-Large Director of the Board of the Food and Drug Law Institute (FDLI). The appointment recognizes Godfrey’s leadership and commitment to FDLI’s mission, as well as his expertise on FDA law and regulations. He will join other highly respected leaders in the field in serving on the FDLI Board beginning in January 2024 for a term of four years.

Godfrey was recently named Co-Chair of Foley Hoag’s Healthcare Department, while also serving as Co-Chair of the FDA Practice Group. He provides strategic regulatory advice to large pharmaceutical, medical device and biotech companies, startups, and trade associations, helping them to navigate challenges relating to the development, manufacturing, approval and promotion of drugs, biologics, medical devices, and combination products.

The Food and Drug Law Institute (FDLI) is a nonprofit membership organization that offers education, training, publications, and professional networking opportunities in the field of food and drug law.